Baldwin Wealth Partners’s Nuvectis Pharma NVCT Stock Holding History

Baldwin Wealth Partners’s Portfolio NVCT Stock Details NVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.03M	Buy	382,015 +3,390	+0.9%	+$38K	0.46%	53
2026 Q1	$2.93M	Sell	378,625 -11,000	-3%	-$94.2K	0.21%	71
2025 Q4	$2.94M	Buy	389,625 +39,164	+11%	+$255K	0.19%	72
2025 Q3	$2.11M	Hold	350,461	–	–	0.14%	82
2025 Q2	$2.62M	Sell	350,461 -8,000	-2%	-$72.5K	0.18%	74
2025 Q1	$3.5M	Buy	358,461 +2,500	+0.7%	+$18K	0.25%	64
2024 Q4	$1.93M	Buy	355,961 +181,831	+104%	+$1.14M	0.13%	84
2024 Q3	$1.1M	Buy	174,130 +5,500	+3%	+$36.2K	0.07%	123
2024 Q2	$1.07M	Buy	168,630 +14,500	+9%	+$98.6K	0.08%	100
2024 Q1	$1.26M	Buy	154,130 +12,090	+9%	+$103K	0.1%	100
2023 Q4	$1.18M	Buy	142,040 +25,660	+22%	+$229K	0.09%	99
2023 Q3	$1.5M	Buy	116,380 +26,319	+29%	+$381K	0.13%	91
2023 Q2	$1.44M	Sell	90,061 -53,739	-37%	-$858K	0.12%	99
2023 Q1	$1.89M	Buy	143,800 +10,500	+8%	+$106K	0.16%	92
2022 Q4	$1,000K	Buy	133,300 +300	+0.2%	+$2.15K	0.09%	112
2022 Q3	$943K	Buy	133,000 +12,000	+10%	+$112K	0.13%	71
2022 Q2	$1.35M	Buy	+121,000	New	+$1.5M	0.18%	61

Other funds holding NVCT

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return

AWM

Austin Wealth Management Austin, Texas $473M AUM 18.73% 1-Year Est. Return

NBC Securities Birmingham, Alabama $1.48B AUM 31.07% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

SCM

Sterling Capital Management Charlotte, North Carolina $5.9B AUM 29.63% 1-Year Est. Return

Baldwin Wealth Partners's NVCT Position: Q2 2026 in Review

Baldwin Wealth Partners increased its Nuvectis Pharma (NVCT) stake by 0.9% in Q2 2026, buying an estimated $38K and bringing the position to 382,015 shares worth $7.03M. The position accounts for 0.46% of the portfolio, ranked #53.

Baldwin Wealth Partners first reported a position in NVCT in Q2 2022 and has held it in 17 quarters since. 15 funds tracked by Wall St. Rank hold NVCT as of Q2 2026.

Baldwin Wealth Partners held 382,015 shares of Nuvectis Pharma worth $7.03M as of Q2 2026.
Baldwin Wealth Partners bought 3,390 Nuvectis Pharma shares in Q2 2026, an estimated $38K.
Nuvectis Pharma made up 0.46% of Baldwin Wealth Partners's portfolio in Q2 2026, its #53 holding.
Baldwin Wealth Partners first reported a position in Nuvectis Pharma in Q2 2022 and has held it in 17 quarters since.
15 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q2 2026.

Based on Baldwin Wealth Partners's 13F filing for Q2 2026, filed 14 Jul 2026.